Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DNASE1L3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | DNASE1L3 Recombinant Protein (Mature Domain); High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. | View DNASE1L3 Products |
| Antigen (Mutant) | DNASE1L3 Catalytic Dead Mutant (H134A); Sequence Verified control for enzymatic assays. Theoretical MW confirmed. | View DNASE1L3 Products |
| Gene Delivery | DNASE1L3 Promise-ORF / Lentivirus; Full-length ORF for stable cell lines and secreted expression. | View DNASE1L3 Products |
| Benchmark Ab | Anti-DNASE1L3 Neutralizing Antibody (Chimeric); Recombinant positive control for activity blockade. | View DNASE1L3 Products |
| Validator | DNASE1L3 siRNA Set; For knockdown and specificity verification. | View DNASE1L3 Products |
| Related Target: DNASE1 | DNASE1 (Canonical DNase I); Paralog comparison and cross-reactivity testing. | View DNASE1 Products |
| Related Target: PAD4 | Peptidyl Arginine Deiminase 4; NETosis pathway partner; synergistic target for autoimmune modulation. | View PAD4 Products |
| Related Target: TREX1 | Three Prime Repair Exonuclease 1; Synergistic pathway for cytosolic DNA sensing and clearance. | View TREX1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity Quantification (DNA degradation kinetics) | High-purity (>95%) WT and Catalytic Dead (H134A) proteins; Endotoxin <1EU/ug ensuring no contaminant interference in kinetic assays |
| NETosis Modulation Studies (Neutrophil Extracellular Trap degradation) | Native glycosylation (HEK293 expressed) preserving conformational stability for physiological NET degradation assays |
| Paralog Selectivity (vs. DNASE1) | Strict sequence verification by mass spec; Unique C-terminal domain intact for specificity testing |
| Neutralizing Antibody Screening | Clinical Benchmark Antibodies (Biosimilars) included for assay validation |
| False Positives in Activity Assays | Validated siRNA included for specificity checks and knockdown validation |
| Subfamily Counter-Screening | Homolog panel proteins (DNASE1) strictly verified by theoretical MW and sequence |
| Lack of Positive Controls | Recombinant positive control antibodies provided for assay benchmarking |
Live DNASE1L3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DNASE1L3 therapeutics is intensifying, with major players shifting focus from traditional immunosuppressants to nuclease replacement strategies and targeted NETosis modulators. As first-generation recombinant protein therapies reach preclinical milestones, the next wave of R&D is targeting combination approaches with PAD4 inhibitors and STING pathway modulators for systemic lupus erythematosus (SLE) and metastatic cancer indications. Key somatic mutations have been identified in cancer samples (e.g., dbSNP:rs763778721 and rs12491947) and are linked to diminished enzymatic activity, underscoring the importance of mutation-specific assay development. Both enzyme replacement and mRNA delivery modalities are being explored to address monogenic SLE and systemic scleroderma. Emerging resistance mechanisms may involve anti-drug antibodies or compensatory upregulation of DNASE1, driving demand for dual-target strategies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein (Enzyme Replacement) | Biotech/Academic Consortia | SLE, Autoimmune Vasculitis | Enzymatic Activity Assay (Need high-purity WT vs H134A mutant pair) |
| Neutralizing mAb | Immuno-oncology Startups | Solid Tumors (NET-mediated metastasis) | Epitope Mapping (Need conformationally intact antigen with native glycosylation) |
| Gene Therapy | Gene Delivery Platforms | Monogenic SLE | Expression Validation (Need Lentivirus for stable cell line construction) |
| mRNA Therapy | Gene Therapy Companies | Monogenic Autoimmune | Expression Validation (Need specific Benchmark Abs for detection) |
| Small Molecule Inhibitor | Discovery Stage | Inflammatory Disorders | Selectivity Assay (Need DNASE1 vs DNASE1L3 ortholog proteins) |